Share Price and Basic Stock Data
Last Updated: January 24, 2026, 5:41 pm
| PEG Ratio | 10.49 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ganga Pharmaceuticals Ltd, operating in the pharmaceuticals sector, reported a share price of ₹11.8 and a market capitalization of ₹6.98 Cr. Over the years, the company has experienced fluctuations in its revenue generation. Sales stood at ₹2.47 Cr for the fiscal year ending March 2023, with a slight increase to ₹2.58 Cr in March 2024 but a projected decline to ₹2.48 Cr in March 2025. Quarterly sales figures show a recovery trend, with ₹1.32 Cr reported in September 2023, reflecting a year-on-year increase from ₹1.35 Cr in September 2022. However, a consistent pattern of rising expenses has been noted, which hindered operating profit margins, recorded at -1.46% for the latest period. The company’s ability to sustain revenue growth amidst rising operational costs remains a challenge, necessitating a closer look at operational efficiencies and market positioning.
Profitability and Efficiency Metrics
Ganga Pharmaceuticals’ profitability metrics reveal a concerning trend. The operating profit margin (OPM) recorded -1.46%, indicating that the company is currently operating at a loss. The net profit for the fiscal year ending March 2023 was a mere ₹0.01 Cr, representing a minimal increase from ₹0.03 Cr in March 2022. The return on equity (ROE) was reported at 1.13%, while return on capital employed (ROCE) stood at 3.18%, both of which are below acceptable industry benchmarks. The interest coverage ratio of 1.79x suggests that the company is barely able to meet its interest obligations, further raising concerns about its financial stability. The cash conversion cycle (CCC) has remained relatively long at 403.19 days, indicating inefficiencies in managing working capital, particularly in inventory and receivables management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ganga Pharmaceuticals reveals a mixed picture of financial health. With total borrowings at ₹1.56 Cr against reserves of ₹2.37 Cr, the company’s debt-to-equity ratio stands at 0.19, which is relatively low and suggests limited leverage. However, the current ratio of 4.28x indicates that the company maintains a strong liquidity position, which is critical for covering short-term liabilities. The price-to-book value (P/BV) ratio is reported at 0.68x, suggesting that the stock is undervalued relative to its book value, potentially making it attractive for value investors. Nevertheless, the company’s overall financial performance is tempered by its low profitability margins and high operational costs, which could affect long-term sustainability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ganga Pharmaceuticals Ltd has shifted significantly, with promoter holdings declining from 66.71% in early 2021 to 50.91% as of September 2025. This reduction in promoter stake may raise concerns regarding insider confidence in the company’s future prospects. Conversely, public shareholding has increased from 33.29% to 49.09% during the same period, indicating a growing interest among retail investors. The total number of shareholders stood at 366 as of September 2025, reflecting a stable base of investor participation. Despite the changes in shareholder composition, the declining promoter stake could signal potential issues in governance or strategic direction that may affect investor sentiment moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Ganga Pharmaceuticals faces both opportunities and risks. The company’s strong liquidity position and low debt levels provide a buffer against potential downturns, while the recent uptick in sales figures suggests a recovery in demand. However, the persistent negative operating margins and inefficiencies in capital management pose significant risks. The company must address its high operational costs and improve its cash conversion cycle to enhance profitability. Additionally, the decline in promoter holdings could impact strategic decision-making and market perceptions. For Ganga Pharmaceuticals to regain investor trust and improve its financial standing, a focused approach on operational efficiency and market expansion is essential. The path forward will hinge on management’s ability to execute these strategies effectively, ensuring that the business can achieve sustainable growth and profitability in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 197/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,463 Cr. | 318 | 479/192 | 71.7 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,525.73 Cr | 1,087.19 | 47.43 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.38 | 1.70 | 1.14 | 1.23 | 1.25 | 1.24 | 1.35 | 1.23 | 1.32 | 1.42 | 1.31 | 1.33 | 1.37 |
| Expenses | 1.10 | 1.60 | 1.07 | 1.28 | 1.23 | 1.23 | 1.28 | 1.30 | 1.27 | 1.41 | 1.42 | 1.33 | 1.39 |
| Operating Profit | 0.28 | 0.10 | 0.07 | -0.05 | 0.02 | 0.01 | 0.07 | -0.07 | 0.05 | 0.01 | -0.11 | 0.00 | -0.02 |
| OPM % | 20.29% | 5.88% | 6.14% | -4.07% | 1.60% | 0.81% | 5.19% | -5.69% | 3.79% | 0.70% | -8.40% | 0.00% | -1.46% |
| Other Income | 0.08 | 0.09 | 0.07 | 0.19 | 0.11 | 0.15 | 0.12 | 0.18 | 0.09 | 0.15 | 0.29 | 0.14 | 0.15 |
| Interest | 0.12 | 0.12 | 0.09 | 0.10 | 0.10 | 0.09 | 0.12 | 0.07 | 0.09 | 0.09 | 0.09 | 0.09 | 0.07 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 |
| Profit before tax | 0.21 | 0.04 | 0.02 | 0.01 | 0.00 | 0.04 | 0.04 | 0.01 | 0.02 | 0.05 | 0.07 | 0.03 | 0.03 |
| Tax % | 23.81% | 25.00% | 50.00% | 100.00% | 25.00% | 25.00% | 0.00% | 50.00% | 20.00% | 57.14% | -66.67% | 33.33% | |
| Net Profit | 0.16 | 0.03 | 0.02 | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 | 0.02 | 0.03 | 0.02 | 0.06 | 0.02 |
| EPS in Rs | 0.39 | 0.07 | 0.05 | 0.00 | 0.00 | 0.07 | 0.07 | 0.02 | 0.05 | 0.06 | 0.04 | 0.12 | 0.03 |
Last Updated: December 26, 2025, 9:06 pm
Below is a detailed analysis of the quarterly data for Ganga Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from 1.33 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Sep 2025, the value is 1.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.33 Cr. (Mar 2025) to 1.39 Cr., marking an increase of 0.06 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -0.02 Cr., marking a decrease of 0.02 Cr..
- For OPM %, as of Sep 2025, the value is -1.46%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -1.46%, marking a decrease of 1.46%.
- For Other Income, as of Sep 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.07 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.09 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 33.33%. The value appears to be increasing, which may not be favorable. It has increased from -66.67% (Mar 2025) to 33.33%, marking an increase of 100.00%.
- For Net Profit, as of Sep 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.04 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.03. The value appears to be declining and may need further review. It has decreased from 0.12 (Mar 2025) to 0.03, marking a decrease of 0.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.66 | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.58 | 2.48 | 2.70 |
| Expenses | 2.43 | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.61 | 2.24 | 2.28 | 2.47 | 2.53 | 2.60 | 2.72 |
| Operating Profit | 0.23 | 0.25 | 0.30 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0.00 | 0.05 | -0.12 | -0.02 |
| OPM % | 8.65% | 10.25% | 12.24% | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | 0.00% | 1.94% | -4.84% | -0.74% |
| Other Income | 0.15 | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.30 | 0.24 | 0.44 | 0.29 |
| Interest | 0.30 | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 | 0.16 |
| Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 |
| Profit before tax | 0.05 | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.09 | 0.06 |
| Tax % | 40.00% | 40.00% | 28.57% | 27.27% | 23.08% | 30.77% | 23.08% | 50.00% | 16.67% | 40.00% | 33.33% | 11.11% | |
| Net Profit | 0.03 | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | 0.08 |
| EPS in Rs | 0.13 | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.10 | 0.17 | 0.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 66.67% | 40.00% | 28.57% | 111.11% | 0.00% | -89.47% | 100.00% | 0.00% | 25.00% | 60.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -26.67% | -11.43% | 82.54% | -111.11% | -89.47% | 189.47% | -100.00% | 25.00% | 35.00% |
Ganga Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -4% |
| 3 Years: | 2% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -16% |
| 3 Years: | 26% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 13% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:55 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.33 | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 | 5.91 |
| Reserves | 0.28 | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 | 2.37 |
| Borrowings | 2.07 | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | 1.56 |
| Other Liabilities | 0.46 | 0.61 | 0.35 | 0.60 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | 0.32 |
| Total Liabilities | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 10.16 |
| Fixed Assets | 0.65 | 0.65 | 0.62 | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | 0.66 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.50 | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 | 0.00 |
| Other Assets | 4.44 | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | 9.50 |
| Total Assets | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 10.16 |
Below is a detailed analysis of the balance sheet data for Ganga Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.91 Cr.. The value appears strong and on an upward trend. It has increased from 4.84 Cr. (Mar 2025) to 5.91 Cr., marking an increase of 1.07 Cr..
- For Reserves, as of Sep 2025, the value is 2.37 Cr.. The value appears strong and on an upward trend. It has increased from 2.29 Cr. (Mar 2025) to 2.37 Cr., marking an increase of 0.08 Cr..
- For Borrowings, as of Sep 2025, the value is 1.56 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.42 Cr. (Mar 2025) to 1.56 Cr., marking an increase of 0.14 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.32 Cr.. The value appears to be improving (decreasing). It has decreased from 0.42 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.10 Cr..
- For Total Liabilities, as of Sep 2025, the value is 10.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.97 Cr. (Mar 2025) to 10.16 Cr., marking an increase of 1.19 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.66 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.66 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 9.50 Cr.. The value appears strong and on an upward trend. It has increased from 8.31 Cr. (Mar 2025) to 9.50 Cr., marking an increase of 1.19 Cr..
- For Total Assets, as of Sep 2025, the value is 10.16 Cr.. The value appears strong and on an upward trend. It has increased from 8.97 Cr. (Mar 2025) to 10.16 Cr., marking an increase of 1.19 Cr..
Notably, the Reserves (2.37 Cr.) exceed the Borrowings (1.56 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.84 | -1.89 | -1.89 | -1.83 | -1.73 | -1.45 | -1.09 | -1.70 | -1.89 | -1.83 | -1.31 | -1.54 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94.68 | 109.20 | 140.04 | 173.48 | 211.25 | 141.18 | 130.62 | 131.85 | 140.02 | 131.52 | 130.16 | 133.93 |
| Inventory Days | 312.46 | 288.16 | 374.86 | 385.66 | 358.71 | 341.26 | 296.56 | 332.62 | 330.51 | 347.34 | 362.08 | 353.03 |
| Days Payable | 105.08 | 118.01 | 98.65 | 182.50 | 330.39 | 163.21 | 159.69 | 129.52 | 152.32 | 170.73 | 29.20 | 83.77 |
| Cash Conversion Cycle | 302.07 | 279.35 | 416.26 | 376.64 | 239.56 | 319.23 | 267.49 | 334.96 | 318.21 | 308.13 | 463.04 | 403.19 |
| Working Capital Days | 222.29 | 142.11 | 467.80 | 428.84 | 417.14 | 387.96 | 449.23 | 477.56 | 503.45 | 477.31 | 639.46 | 731.47 |
| ROCE % | 7.87% | 8.03% | 6.80% | 6.14% | 5.84% | 7.26% | 7.23% | 3.30% | 3.46% | 3.28% | 3.06% | 3.18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.16 | 0.11 | 0.10 | 0.09 | 0.05 |
| Diluted EPS (Rs.) | 0.12 | 0.07 | 0.10 | 0.09 | 0.05 |
| Cash EPS (Rs.) | 0.25 | 0.19 | 0.23 | 0.22 | 0.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.74 | 14.58 | 13.42 | 13.32 | 13.23 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.74 | 14.58 | 13.42 | 13.32 | 13.23 |
| Revenue From Operations / Share (Rs.) | 5.45 | 5.66 | 6.37 | 6.13 | 5.85 |
| PBDIT / Share (Rs.) | 0.66 | 0.61 | 0.74 | 0.74 | 0.70 |
| PBIT / Share (Rs.) | 0.56 | 0.51 | 0.60 | 0.60 | 0.57 |
| PBT / Share (Rs.) | 0.19 | 0.13 | 0.13 | 0.12 | 0.09 |
| Net Profit / Share (Rs.) | 0.16 | 0.09 | 0.09 | 0.09 | 0.05 |
| PBDIT Margin (%) | 12.12 | 10.86 | 11.71 | 12.08 | 12.01 |
| PBIT Margin (%) | 10.35 | 9.06 | 9.53 | 9.88 | 9.75 |
| PBT Margin (%) | 3.59 | 2.31 | 2.05 | 2.05 | 1.57 |
| Net Profit Margin (%) | 2.99 | 1.70 | 1.51 | 1.52 | 0.85 |
| Return on Networth / Equity (%) | 1.10 | 0.66 | 0.72 | 0.70 | 0.37 |
| Return on Capital Employeed (%) | 3.70 | 3.32 | 4.05 | 3.89 | 3.82 |
| Return On Assets (%) | 0.88 | 0.53 | 0.49 | 0.47 | 0.26 |
| Long Term Debt / Equity (X) | 0.03 | 0.05 | 0.11 | 0.16 | 0.12 |
| Total Debt / Equity (X) | 0.19 | 0.19 | 0.33 | 0.33 | 0.29 |
| Asset Turnover Ratio (%) | 0.29 | 0.32 | 0.32 | 0.31 | 0.31 |
| Current Ratio (X) | 4.28 | 4.81 | 2.72 | 2.91 | 2.86 |
| Quick Ratio (X) | 3.55 | 3.77 | 2.09 | 2.23 | 2.15 |
| Inventory Turnover Ratio (X) | 2.18 | 1.09 | 1.15 | 1.13 | 1.31 |
| Interest Coverage Ratio (X) | 1.79 | 1.61 | 1.56 | 1.54 | 1.47 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 1.25 | 1.20 | 1.19 | 1.10 |
| Enterprise Value (Cr.) | 6.04 | 13.13 | 7.46 | 5.95 | 4.59 |
| EV / Net Operating Revenue (X) | 2.29 | 4.80 | 2.88 | 2.39 | 1.93 |
| EV / EBITDA (X) | 18.89 | 44.20 | 24.61 | 19.80 | 16.09 |
| MarketCap / Net Operating Revenue (X) | 1.87 | 4.32 | 2.19 | 1.67 | 1.28 |
| Price / BV (X) | 0.68 | 1.67 | 1.04 | 0.76 | 0.56 |
| Price / Net Operating Revenue (X) | 1.87 | 4.32 | 2.19 | 1.67 | 1.28 |
| EarningsYield | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ganga Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 5. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 24) to 0.12, marking an increase of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has increased from 0.19 (Mar 24) to 0.25, marking an increase of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.74. It has increased from 14.58 (Mar 24) to 14.74, marking an increase of 0.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.74. It has increased from 14.58 (Mar 24) to 14.74, marking an increase of 0.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 5.45. It has decreased from 5.66 (Mar 24) to 5.45, marking a decrease of 0.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 2. It has increased from 0.61 (Mar 24) to 0.66, marking an increase of 0.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.56. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.56, marking an increase of 0.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 2. It has increased from 0.09 (Mar 24) to 0.16, marking an increase of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 10.86 (Mar 24) to 12.12, marking an increase of 1.26.
- For PBIT Margin (%), as of Mar 25, the value is 10.35. This value is within the healthy range. It has increased from 9.06 (Mar 24) to 10.35, marking an increase of 1.29.
- For PBT Margin (%), as of Mar 25, the value is 3.59. This value is below the healthy minimum of 10. It has increased from 2.31 (Mar 24) to 3.59, marking an increase of 1.28.
- For Net Profit Margin (%), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.99, marking an increase of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 15. It has increased from 0.66 (Mar 24) to 1.10, marking an increase of 0.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.70. This value is below the healthy minimum of 10. It has increased from 3.32 (Mar 24) to 3.70, marking an increase of 0.38.
- For Return On Assets (%), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 5. It has increased from 0.53 (Mar 24) to 0.88, marking an increase of 0.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 24) to 0.03, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.19.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.29. It has decreased from 0.32 (Mar 24) to 0.29, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 4.28. This value exceeds the healthy maximum of 3. It has decreased from 4.81 (Mar 24) to 4.28, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 2. It has decreased from 3.77 (Mar 24) to 3.55, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 4. It has increased from 1.09 (Mar 24) to 2.18, marking an increase of 1.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 1.61 (Mar 24) to 1.79, marking an increase of 0.18.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has increased from 1.25 (Mar 24) to 1.44, marking an increase of 0.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.04. It has decreased from 13.13 (Mar 24) to 6.04, marking a decrease of 7.09.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.80 (Mar 24) to 2.29, marking a decrease of 2.51.
- For EV / EBITDA (X), as of Mar 25, the value is 18.89. This value exceeds the healthy maximum of 15. It has decreased from 44.20 (Mar 24) to 18.89, marking a decrease of 25.31.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 4.32 (Mar 24) to 1.87, marking a decrease of 2.45.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.67 (Mar 24) to 0.68, marking a decrease of 0.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 4.32 (Mar 24) to 1.87, marking a decrease of 2.45.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ganga Pharmaceuticals Ltd:
- Net Profit Margin: 2.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 88.6 (Industry average Stock P/E: 47.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Gangatat, Dhanvantary Marg, Palghar Maharashtra 401305 | ayurvedganga@gmail.com www.ayurvedganga.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjay Vyankatesh Kulkarni | Chairman & Non-Exe.Director |
| Mr. Bharat Brijmohan Sharma | Managing Director & CEO |
| Mrs. Srijna Bharat Sharma | Whole Time Director |
| Mr. Munna Baijnath Chaurasia | Independent Director |
| Mr. Aman Mukesh Chaudhari | Independent Director |
FAQ
What is the intrinsic value of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd's intrinsic value (as of 26 January 2026) is ₹12.41 which is 3.42% higher the current market price of ₹12.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹7.09 Cr. market cap, FY2025-2026 high/low of ₹14.8/9.25, reserves of ₹2.37 Cr, and liabilities of ₹10.16 Cr.
What is the Market Cap of Ganga Pharmaceuticals Ltd?
The Market Cap of Ganga Pharmaceuticals Ltd is 7.09 Cr..
What is the current Stock Price of Ganga Pharmaceuticals Ltd as on 26 January 2026?
The current stock price of Ganga Pharmaceuticals Ltd as on 26 January 2026 is ₹12.0.
What is the High / Low of Ganga Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ganga Pharmaceuticals Ltd stocks is ₹14.8/9.25.
What is the Stock P/E of Ganga Pharmaceuticals Ltd?
The Stock P/E of Ganga Pharmaceuticals Ltd is 88.6.
What is the Book Value of Ganga Pharmaceuticals Ltd?
The Book Value of Ganga Pharmaceuticals Ltd is 14.0.
What is the Dividend Yield of Ganga Pharmaceuticals Ltd?
The Dividend Yield of Ganga Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Ganga Pharmaceuticals Ltd?
The ROCE of Ganga Pharmaceuticals Ltd is 3.18 %.
What is the ROE of Ganga Pharmaceuticals Ltd?
The ROE of Ganga Pharmaceuticals Ltd is 1.13 %.
What is the Face Value of Ganga Pharmaceuticals Ltd?
The Face Value of Ganga Pharmaceuticals Ltd is 10.0.